{"corpus_id":1545777,"paper_sha":"0b003562258adaaa1ce99ac3326424ca08c8e7e1","doi":"10.1056/NEJM200005183422004","arxiv_id":null,"pmid":10816186,"pmcid":null,"mag_id":2322912881,"dblp_id":null,"acl_id":null,"title":"A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.","year":2000,"publication_date":"2000-05-18","venue":"New England Journal of Medicine","journal":{"name":"The New England journal of medicine","pages":"\n          1484-91\n        ","volume":"342 20"},"journal_issn":null,"journal_title":null,"publication_types":["Study","JournalArticle","ClinicalTrial"],"pubmed_pub_types":["Clinical Trial","Comparative Study","Journal Article","Multicenter Study","Randomized Controlled Trial","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Medicine"],"reference_count":38,"citation_count":1537,"influential_citation_count":57,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Aged","mj":false,"ui":"D000368"},{"d":"Antiparkinson Agents","mj":false,"qs":[{"q":"adverse effects","mj":false,"ui":"Q000009"},{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D000978"},{"d":"Disease-Free Survival","mj":false,"ui":"D018572"},{"d":"Double-Blind Method","mj":false,"ui":"D004311"},{"d":"Drug Therapy, Combination","mj":false,"ui":"D004359"},{"d":"Dyskinesia, Drug-Induced","mj":false,"qs":[{"q":"epidemiology","mj":false,"ui":"Q000453"},{"q":"etiology","mj":true,"ui":"Q000209"},{"q":"prevention & control","mj":false,"ui":"Q000517"}],"ui":"D004409"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Incidence","mj":false,"ui":"D015994"},{"d":"Indoles","mj":false,"qs":[{"q":"adverse effects","mj":false,"ui":"Q000009"},{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D007211"},{"d":"Levodopa","mj":false,"qs":[{"q":"adverse effects","mj":false,"ui":"Q000009"},{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D007980"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Middle Aged","mj":false,"ui":"D008875"},{"d":"Parkinson Disease","mj":false,"qs":[{"q":"drug therapy","mj":true,"ui":"Q000188"}],"ui":"D010300"},{"d":"Prospective Studies","mj":false,"ui":"D011446"},{"d":"Risk Factors","mj":false,"ui":"D012307"}],"chemicals":[{"n":"Antiparkinson Agents","ui":"D000978","reg":"0"},{"n":"Indoles","ui":"D007211","reg":"0"},{"n":"ropinirole","ui":"C046649","reg":"030PYR8953"},{"n":"Levodopa","ui":"D007980","reg":"46627O600J"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://www.nejm.org/doi/pdf/10.1056/NEJM200005183422004?articleTools=true","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/0b003562258adaaa1ce99ac3326424ca08c8e7e1","s2_open_access_license":null,"s2_open_access_status":"BRONZE","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"BACKGROUND: There is debate about whether the initial treatment for patients with Parkinson's disease should be levodopa or a dopamine agonist. METHODS: In this prospective, randomized, double-blind study, we compared the safety and efficacy of the dopamine D2-receptor agonist ropinirole with that of levodopa over a period of five years in 268 patients with early Parkinson's disease. If symptoms were not adequately controlled by the assigned study medication, patients could receive supplementary levodopa, administered in an open-label fashion. The primary outcome measure was the occurrence of dyskinesia. RESULTS: Eighty-five of the 179 patients in the ropinirole group (47 percent) and 45 of the 89 patients in the levodopa group (51 percent) completed all five years of the study. In the ropinirole group 29 of the 85 patients (34 percent) received no levodopa supplementation. The analysis of the time to dyskinesia showed a significant difference in favor of ropinirole (hazard ratio for remaining free of dyskinesia, 2.82; 95 percent confidence interval, 1.78 to 4.44; P<0.001). At five years, the cumulative incidence of dyskinesia (excluding the three patients who had dyskinesia at base line), regardless of levodopa supplementation, was 20 percent (36 of 177 patients) in the ropinirole group and 45 percent (40 of 88 patients) in the levodopa group. There was no significant difference between the two groups in the mean change in scores for activities of daily living among those who completed the study. Adverse events led to the early withdrawal from the study of 48 of 179 patients in the ropinirole group (27 percent) and 29 of 89 patients in the levodopa group (33 percent). The mean (+/-SD) daily doses given by the end of the study were 16.5+/-6.6 mg of ropinirole (plus 427+/-221 mg of levodopa in patients who received supplementation) and 753+/-398 mg of levodopa (including supplements). CONCLUSIONS: Early Parkinson's disease can be managed successfully for up to five years with a reduced risk of dyskinesia by initiating treatment with ropinirole alone and supplementing it with levodopa if necessary.","claims":[{"public_id":"cl_7561bf0cde4b5dc3292f6eaa9a27dd5e","status":"active","text":"Among participants who completed the study, mean change in activities of daily living scores did not differ significantly between the treatment groups.","confidence":0.88,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_7561bf0cde4b5dc3292f6eaa9a27dd5e"},{"public_id":"cl_ec8072529061f1ddc76c069b38c08083","status":"active","text":"Five-year cumulative dyskinesia incidence was lower with ropinirole than with levodopa, at 20 percent versus 45 percent.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_ec8072529061f1ddc76c069b38c08083"},{"public_id":"cl_a5a1778c1199119b10b3f8cc8c494def","status":"active","text":"Initiating treatment with ropinirole and adding levodopa only if needed reduces the risk of dyskinesia over five years in early Parkinson's disease.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_a5a1778c1199119b10b3f8cc8c494def"},{"public_id":"cl_a7c0db51987d0d014ce3e08ed45fec80","status":"active","text":"Time to dyskinesia favored ropinirole over levodopa, with a hazard ratio for remaining free of dyskinesia of 2.82.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_a7c0db51987d0d014ce3e08ed45fec80"}],"concepts":[{"public_id":"co_042905bd733861a71c3f31b1a071ab5f","status":"active","name":"cumulative incidence of dyskinesia","description":"The proportion of patients who developed dyskinesia over the five-year follow-up period.","types":["outcome measure"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_042905bd733861a71c3f31b1a071ab5f"},{"public_id":"co_3b535a9153ac98acab67406a044d419b","status":"active","name":"time to dyskinesia","description":"The duration from treatment initiation until dyskinesia occurred.","types":["outcome measure"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_3b535a9153ac98acab67406a044d419b"},{"public_id":"co_441939db84c180c031c67b8d5b1db92e","status":"active","name":"ropinirole","description":"A dopamine D2-receptor agonist used as an initial treatment for early Parkinson's disease in the study.","types":["drug","dopamine agonist"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_441939db84c180c031c67b8d5b1db92e"},{"public_id":"co_5b9746fad0e3aa48d55957a043f3ab06","status":"active","name":"prospective, randomized, double-blind study","description":"A trial design involving prospective follow-up, random assignment, and blinded treatment allocation.","types":["study design"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_5b9746fad0e3aa48d55957a043f3ab06"},{"public_id":"co_787cab2c9bb2f17968b7f9ba354a77a2","status":"active","name":"hazard ratio for remaining free of dyskinesia","description":"A comparative survival analysis statistic summarizing the relative time until dyskinesia between treatment groups.","types":["effect measure"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_787cab2c9bb2f17968b7f9ba354a77a2"},{"public_id":"co_7f147b3761f805e93f53fa2230affe8e","status":"active","name":"levodopa","description":"A dopaminergic medication used as comparator and as supplementary open-label treatment when symptoms were not adequately controlled.","types":["drug","treatment"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_7f147b3761f805e93f53fa2230affe8e"},{"public_id":"co_c23453207788527a0a640fa7c3679390","status":"active","name":"activities of daily living","description":"A functional status measure assessing the ability to perform everyday tasks.","types":["outcome measure"],"aliases":["ADL"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_c23453207788527a0a640fa7c3679390"},{"public_id":"co_d65a87e0b8ebf999e461f7ac640fcf69","status":"active","name":"open-label levodopa supplementation","description":"Additional levodopa given without blinding when assigned study medication did not adequately control symptoms.","types":["treatment","study procedure"],"aliases":["levodopa supplementation"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_d65a87e0b8ebf999e461f7ac640fcf69"},{"public_id":"co_e86cc5156b7391e83a315cb69d957ec3","status":"active","name":"dyskinesia","description":"Involuntary movement disorder used as the primary outcome measure in the trial.","types":["outcome","adverse effect"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_e86cc5156b7391e83a315cb69d957ec3"},{"public_id":"co_f3b361d3429e8cb8977fc0ea4fbc0c52","status":"active","name":"early Parkinson's disease","description":"An early stage of Parkinson's disease in which patients were enrolled and followed for five years.","types":["condition"],"aliases":["PD"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_f3b361d3429e8cb8977fc0ea4fbc0c52"}],"external_ids":{"DOI":"10.1056/NEJM200005183422004","ArXiv":null,"PubMed":10816186,"PubMedCentral":null,"MAG":2322912881,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://www.nejm.org/doi/pdf/10.1056/NEJM200005183422004?articleTools=true","landing_url":"https://www.semanticscholar.org/paper/0b003562258adaaa1ce99ac3326424ca08c8e7e1","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":null,"status":"BRONZE","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":631477,"paper_uid":"dea74aa3-cc82-490d-b4a8-dfd3ecee1f9e","canonical_identity":{"paper_id":631477,"paper_uid":"dea74aa3-cc82-490d-b4a8-dfd3ecee1f9e","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/1545777"}